Lamotrigine for Bipolar Disorder

The approval is narrower than the reputation. Lamotrigine is approved for the maintenance treatment of bipolar I disorder, to delay the time to occurrence of mood episodes in adults treated for acute mood episodes with standard therapy. The same label carries an explicit Limitations of Use: treatment of acute manic or mixed episodes is not recommended, and effectiveness in the acute treatment of mood episodes has not been established.

If you are in an episode right now, this is not the drug that ends it.

The label says the precise mechanism in mood disorders is unknown, and describes the best supported action as inhibition of voltage-gated sodium channels, which reduces release of the excitatory neurotransmitter glutamate. That is a different lever from lithium or from an atypical antipsychotic. In practice it means almost no sedation, no dopamine blockade, and none of the acute blunting that makes an antipsychotic useful on day two of a manic episode.

Because of the rash risk, the dose has to climb slowly, so it cannot be loaded. CANMAT and ISBD note that the slow titration makes lamotrigine a poor fit when a rapid response is needed. You reach the 100 mg step around week five and the 200 mg target around week six or seven. Judging whether it is working is a question of months without an episode. How you feel on a given afternoon is not the measure.

Lamotrigine carries a boxed warning for serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis and rash related death. Label incidence of rash requiring hospitalization and withdrawal is roughly 0.3% to 0.8% in ages 2 to 17 and 0.08% to 0.3% in adults. In the adult bipolar program the rates were 0.08%, or 1 of 1,233 on initial monotherapy, and 0.13%, or 2 of 1,538 on adjunctive therapy. Rare, but not theoretical, and not something to discount.

Timing and cause are both known. Nearly all life threatening rashes occurred within 2 to 8 weeks of starting, and the label names three modifiable drivers: coadministration of valproate, exceeding the recommended starting dose, and exceeding the recommended escalation rate. Adding valproate raised rash related hospitalization to 1%, or 6 of 584, against 0.16%, or 4 of 2,398, without it. The EuroSCAR case control study likewise found the elevated risk restricted to the first weeks of use.

The label instruction is blunt: discontinue at the first sign of rash unless the rash is clearly not drug related. Any rash, any mouth or eye involvement, fever, or swollen glands while you are titrating warrants immediate contact with the prescriber the same day. Restarting after a rash related stop is discouraged unless the benefit clearly outweighs the risk. This is the one part of lamotrigine treatment that should never be self managed or slept on.

The standard bipolar schedule with no interacting drug runs 25 mg daily for weeks 1 and 2, 50 mg daily for weeks 3 and 4, 100 mg in week 5, then the 200 mg target in weeks 6 and 7. The label also notes no added benefit was shown at 400 mg over 200 mg, and doses above 200 mg are not recommended.

That slow ramp is not caution for its own sake. It is the safety intervention, and escalating faster is one of the three named rash risk factors.

Two other columns exist and picking the wrong one is a dosing error with a skin consequence. With valproate on board the ramp halves at every step: 25 mg every other day for weeks 1 and 2, 25 mg daily for weeks 3 and 4, 50 mg in week 5, target 100 mg. With carbamazepine, phenytoin, phenobarbital, primidone or rifampin and no valproate, it roughly doubles: 50 mg daily to start, climbing to a 400 mg target by week 7.

The restart rule is the one most often missed. If you stop for more than five half lives, the label directs restarting at the initial dosing recommendations and climbing again from 25 mg. Resuming a missed week straight back at 200 mg skips the gradual escalation the label treats as the safety step, and re-enters the highest risk window at full dose. Coming off in the other direction should be a taper over at least two weeks, about 50% per week unless safety demands faster.

Two randomized, placebo controlled maintenance trials of up to 18 months sit behind the approval. Adults were stabilized on open label lamotrigine first, and 638 of 1,315 enrolled reached the double blind phase, where median time to intervention for a mood episode was 197 days on lamotrigine, 184 days on lithium and 86 days on placebo. Both active drugs beat placebo. Note the open label filter: these are results in adults who had already tolerated the drug.

Split by pole, the picture sharpens. In the recently manic trial, 175 randomized, lamotrigine was superior to placebo for time to a depressive episode while lithium was superior for time to a manic, hypomanic or mixed episode. In the recently depressed trial, 463 randomized, median survival was 200 days on lamotrigine, 170 on lithium and 93 on placebo, with interventions for depression outnumbering interventions for mania by close to three to one.

The limits are as informative as the wins. In the pooled analysis, once results were adjusted for the index mood episode, only lithium remained superior to placebo for mania. CANMAT and ISBD also record that lamotrigine did not separate from placebo in maintenance treatment of rapid cycling bipolar I. The honest framing is a drug that holds the depressive floor better than it caps the manic ceiling.

For acute bipolar depression the evidence is thinner than the drug's reputation suggests. A participant level meta analysis of five randomized trials covering 1,072 adults found a relative risk of response of 1.27 on the Hamilton scale against placebo. Severity decided who benefited: the advantage was significant at a baseline HRSD above 24, RR 1.47, and not significant at 24 or below, RR 1.07. Real, modest, and concentrated in more severe depression.

For acute mania the guideline verdict is flat. CANMAT and ISBD list lamotrigine as Level 1 negative evidence and not recommended for acute mania, which is as clear as a guideline gets. The pharmacology agrees with the trials here, because the seven week titration alone consumes the entire window in which an acute manic episode has to be brought under control.

Nothing about swallowing a first 25 mg tablet changes anything that same week, or the week after it.

It gets asked for by name by those whose bipolar course has been mostly depressive, who have gained weight on an atypical antipsychotic, or who would rather avoid the blood draws that lithium requires. Whether any of that describes your illness is a clinical judgment rather than a self assessment. Your prescriber weighs the diagnosis, the episode history and everything else you take before writing it, and nothing on this page is medical advice.

The metabolic contrast is most of why lamotrigine gets requested. Across the 52 week maintenance trials, obese participants lost a mean 4.2 kg on lamotrigine while gaining 6.1 kg on lithium, against 0.6 kg lost on placebo; in non-obese participants the differences were not significant. CANMAT and ISBD place the highest metabolic risk with clozapine and olanzapine, and also flag weight gain with lithium and divalproex.

Monitoring differs too. The label states that no therapeutic plasma concentration range has been established and dosing is driven by clinical response. There is no lamotrigine equivalent of trough lithium levels, thyroid panels and renal checks every few months. What replaces that ongoing surveillance is intense rash vigilance during the ramp, which is a shorter window but a much sharper one.

The trade is straightforward once you see both trials side by side. Lithium was superior for time to a manic episode; lamotrigine was superior for time to a depressive one. Neither wins everywhere, and the two are often combined rather than chosen between. Which one fits depends on which pole has cost you the most time, and that is a conversation with a prescriber rather than a comparison table to settle alone.

Valproate increases lamotrigine concentrations slightly more than twofold, so both the starting schedule and the target dose drop when the two are combined. Carbamazepine, phenytoin, phenobarbital, primidone and rifampin push the other way, decreasing lamotrigine by roughly 40% and raising the bipolar target to 400 mg a day. Starting or stopping any of these is a planned dose change rather than a coincidence to ride out.

Hormonal contraception is the under discussed one. An estrogen containing pill with 30 mcg ethinyl estradiol and 150 mcg levonorgestrel decreased lamotrigine exposure by about 50%, and the maintenance dose may need to increase by as much as twofold to compensate. Stopping the pill runs the film backwards: one study measured dose corrected lamotrigine concentrations 84% higher after estrogen withdrawal, most of the rise inside the first week.

The pill free week works in the opposite direction from what most expect. During the week of inactive tablets lamotrigine levels do not drop further, they rise transiently, and the label warns this can cause dizziness, ataxia and double vision. The label specifically says dose adjustments limited to the pill free week are not recommended. If that week feels different every month, report it rather than adjusting the dose yourself.

One genetic marker matters. The label reports an approximately 2 to 3 times higher risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in carriers of the HLA-B 1502 allele, which is more common in Han Chinese and Thai ancestry. Unlike the carbamazepine label, this one does not tell you to screen before starting. It says to weigh risks and benefits if the status is already known, warns that genotyping has important limitations, and stresses that a negative result never removes the need for clinical vigilance.

In May 2018 the FDA added hemophagocytic lymphohistiocytosis to Warnings and Precautions, a change stamped in the label revision history for that year under Recent Major Changes. It is a rare immune reaction presenting with fever, rash, enlarged liver or spleen, swollen lymph nodes, low blood counts and a very high ferritin, reported 8 to 24 days after starting. It overlaps confusingly with an ordinary viral illness, which is why fever plus rash in the first month gets evaluated instead of waited out.

Pregnancy registries have not produced a clear overall malformation signal: 2.2% of 1,558 first trimester monotherapy exposures in the international registry, 2.0% of 1,562 in the North American registry and 2.9% of 2,514 in EURAP, against a 2% to 4% background rate. The North American registry did see oral clefts at 3.2 per 1,000, roughly a threefold increase not replicated in the other registries. Levels also fall during pregnancy and rebound after delivery, so dosing needs active management.

The National Average Drug Acquisition Cost is what retail pharmacies pay, surveyed and published by CMS. At the 2026-08-19 effective date, generic lamotrigine 200 mg tablets carried a NADAC of $0.08404 per tablet, with 100 mg at $0.04874 and 25 mg at $0.02705. At the 200 mg maintenance target that works out to about $2.52 of acquisition cost per 30 days. The immediate release generic is among the cheapest drugs in psychiatry. Form matters more than strength here. On the same date extended release 200 mg was $0.61803 per tablet and the orally disintegrating 200 mg was $1.46569, roughly seven and seventeen times the plain tablet. Unless there is a specific swallowing or release reason, the immediate release tablet is where the value sits, and it is worth confirming which form a prescription was actually written for.

Acquisition cost is not your price. Cash retail, discount card pricing and an insurance copay all sit above it and vary widely by pharmacy, and any telehealth consultation fee is separate from the drug itself. What the NADAC figure tells you is that the medication should never be the expensive part of this treatment, so a high quoted monthly price is worth questioning before you accept it.

Lamotrigine for bipolar I is not a lifestyle prescription. Writing it responsibly requires a confirmed bipolar I diagnosis, a look at what stabilized the last acute episode, and an interaction review. Any service willing to issue it from a short questionnaire with no psychiatric evaluation is skipping the step that makes the prescription appropriate in the first place. That call belongs to a licensed clinician who has actually evaluated you, and nothing here substitutes for that assessment.

Four questions separate a serious service from a convenient one. Does the prescriber follow the label titration schedule, and which column applies to you? Will valproate, carbamazepine, phenytoin, phenobarbital, primidone, rifampin and estrogen containing contraception be reviewed before the first dose is written? How do you reach a clinician urgently if a rash appears during weeks 2 through 8? And what happens to your dose if a shipment is late and you miss several days?

Maintenance is measured in months, so continuity of prescriber matters more than how fast the first appointment lands. Confirm the service supports ongoing psychiatric follow up rather than one off refills, that a dose change does not require starting a new intake, and that records transfer if you move care elsewhere. The cheapest option is rarely the one that answers the phone in week three.